Vancouver, British Columbia–(Newsfile Corp. – May 10, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FSE: 6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, today announced that Robert Tessarolo, President and Chief Executive Officer, will participate in a virtual presentation at the Benzinga Global Small Cap Conference taking place from May 13-14, 2021.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7646/83406_caputre.jpg
Benzinga Global Small Cap Presentation Details:
Date: Thursday, May 13, 2021
Time: 2:20 p.m. ET
Livestream Link: https://www.youtube.com/watch?v=oqcBAxa4o5o
Cannot view this video? Visit:
https://www.youtube.com/watch?v=oqcBAxa4o5o
The Benzinga Global Small Cap Conference is designed to bridge the gap between Small Cap publicly traded companies, investors, and traders. By bringing together over 60 high-growth companies, Benzinga offers the opportunity to gain insights on Small Cap companies across a wide range of industries through live company presentations and educational sessions hosted by executives, expert traders and analysts.
Investors interested in joining the NeonMind presentation can register for free at Benzinga Global Small Cap Conference.
About NeonMind Biosciences Inc.
NeonMind is engaged in developing clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. NeonMind has three divisions, a pharmaceutical division engaged in the development of psychedelic compounds, a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings, and a consumer products division with a focus on mushroom-infused products. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.
NeonMind’s consumer division currently sells NeonMind-branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform, and it has plans to launch dietary supplements in the United States this quarter.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
For further information, please contact:
NeonMind Biosciences Inc.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein / Nick Staab
neonmind@kcsa.com
Edge Communications
invest@neonmind.com
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
brittany@exvera.com
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.